Drawing for EVERGLADE PHARMACEUTICALS

USPTO serial 90123194

EVERGLADE PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 6435930Status 701Renewal
Filing date
Status date
Registration date
Jul 27, 2021
Examiner
TARABAN, LAURA KRISTEN
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with EVERGLADE PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
042Pharmaceutical products development; Pharmaceutical research and developmentACTIVEAug 1, 2020
044Pharmaceutical adviceACTIVEAug 1, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 17, 2026NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Oct 17, 20268.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Oct 17, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 21, 2026ES8RTEAS SECTION 8 RECEIVED—
Jul 27, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 18, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 18, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 18, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 11, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 27, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 22, 2021SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 21, 2021CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
May 12, 2021SUPCSTATEMENT OF USE PROCESSING COMPLETE—
May 12, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 28, 2021IUAFUSE AMENDMENT FILED—
Apr 28, 2021EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Mar 16, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 19, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 19, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 30, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 16, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 16, 2020DOCKASSIGNED TO EXAMINER—
Sep 22, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 22, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance